Benzinga · Feb 24, 2026
OR
NASDAQ · ORIC
ORIC Pharmaceuticals, Inc.
Healthcare · Biotechnology
$8.96
Down-$4.22 (-32.00%)
Updated Oct 27, 2026, 3:41 AM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 944.68M
- P/E ratio
- -7.1
- Dividend yield
- 0.00%
- 52-week range
- $7.23 – $14.68
- Volume
- 6.95M
- Avg. volume
- 1.39M
Price performance · ORIC
ORIC price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 26, 2026
ORIC closed at $8.96 after 21 trading sessions, down 32.52% for the selected period.
- Last close
- $8.96
- Period change
- -32.52%
- Period low
- $8.96
- Period high
- $13.85
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 26, 2026 | $13.10 | $13.235 | $8.88 | $8.955 | 6.95M |
| Oct 23, 2026 | $13.10 | $13.49 | $12.73 | $13.17 | 1.39M |
| Oct 22, 2026 | $13.67 | $14.14 | $13.38 | $13.63 | 1.15M |
| Oct 21, 2026 | $13.81 | $14.2044 | $13.7401 | $13.85 | 1.57M |
| Oct 20, 2026 | $12.79 | $14.3099 | $12.52 | $13.78 | 2.02M |
| Oct 19, 2026 | $12.46 | $12.74 | $12.14 | $12.72 | 1.19M |
| Oct 16, 2026 | $12.75 | $12.75 | $12.025 | $12.35 | 946.2K |
| Oct 15, 2026 | $11.74 | $12.89 | $11.53 | $12.77 | 1.56M |
| Oct 14, 2026 | $11.35 | $11.835 | $11.20 | $11.59 | 1.79M |
| Oct 13, 2026 | $11.68 | $11.915 | $11.29 | $11.31 | 1.16M |
| Oct 12, 2026 | $12.06 | $12.255 | $11.73 | $11.81 | 878.26K |
| Oct 9, 2026 | $11.98 | $12.29 | $11.90 | $11.99 | 1.09M |
| Oct 8, 2026 | $11.87 | $12.20 | $10.925 | $12.03 | 2.7M |
| Oct 7, 2026 | $11.83 | $12.425 | $11.805 | $12.01 | 790.78K |
| Oct 6, 2026 | $12.60 | $12.60 | $11.56 | $11.98 | 2.09M |
| Oct 5, 2026 | $12.65 | $12.65 | $11.89 | $12.49 | 1.4M |
| Oct 2, 2026 | $12.72 | $12.925 | $12.165 | $12.205 | 1.23M |
| Oct 1, 2026 | $13.42 | $13.615 | $12.51 | $12.52 | 1.77M |
| Sep 30, 2026 | $13.51 | $14.12 | $13.33 | $13.47 | 1.96M |
| Sep 29, 2026 | $13.23 | $13.42 | $12.76 | $13.37 | 977.26K |
| Sep 28, 2026 | $13.135 | $13.72 | $12.76 | $13.27 | 1.52M |
Latest ORIC news
The latest Smart Investors Daily articles mentioning ORIC.
Stock researchCompany · Overview
Company
Market Activity
Research & News
ORIC research
Overview
Company profile and research snapshot.
Company profile
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $22.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 14, 2026 | JP Morgan | Overweight | — |
| Oct 5, 2026 | Leerink Partners | Outperform | — |
| Sep 23, 2026 | BTIG | Buy | — |
| Aug 10, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 8, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Feb 24, 2026
Citigroup Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $17
Citigroup analyst Yigal Nochomovitz maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and raises the price target from $16 to $17.
Benzinga · Feb 24, 2026
HC Wainwright & Co. Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $25
HC Wainwright & Co. analyst Robert Burns maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and raises the price target from $23 to $25.
Benzinga · Feb 24, 2026
Wedbush Reiterates Outperform on ORIC Pharmaceuticals, Maintains $20 Price Target
Wedbush analyst David Nierengarten reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform and maintains $20 price target.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
